Elosulfase alfa
Vimizim (elosulfase alfa) is an enzyme pharmaceutical. Elosulfase alfa was first approved as Vimizim on 2014-02-14. It is used to treat mucopolysaccharidosis IV in the USA. It has been approved in Europe to treat mucopolysaccharidosis IV.
| Trade Name | Vimizim |
|---|---|
| Common Name | Elosulfase alfa |
| Indication | mucopolysaccharidosis iv |
| Drug Class | Enzymes |
